Larsson Malin K, Larsson Matilda, Nowak Greg, Paradossi Gaio, Brodin Lars-Åke, Sjöberg Birgitta Janerot, Caidahl Kenneth, Bjällmark Anna
Department of Medical Engineering, School of Technology and Health, KTH Royal Institute of Technology, Alfred Nobels Allé 10, 141 52 Huddinge, Sweden.
Cardiovasc Ultrasound. 2014 Jul 3;12:24. doi: 10.1186/1476-7120-12-24.
A novel polymer-shelled contrast agent (CA) with multimodal and target-specific potential was developed recently. To determine its ultrasonic diagnostic features, we evaluated the endocardial border delineation as visualized in a porcine model and the concomitant effect on physiological variables.
Three doses of the novel polymer-shelled CA (1.5 ml, 3 ml, and 5 ml [5 × 10(8) microbubbles (MBs)/ml]) and the commercially available CA SonoVue (1.5 ml [2-5 × 10(8) MBs/ml]) were used. Visual evaluations of ultrasound images of the left ventricle were independently performed by three observers who graded each segment in a 6-segment model as either 0 = not visible, 1 = weakly visible, or 2 = visible. Moreover, the duration of clinically useful contrast enhancement and the left ventricular opacification were determined. During anesthesia, oxygen saturation, heart rate, and arterial pressure were sampled every minute and the effect of injection of CA on these physiological variables was evaluated.
The highest dose of the polymer-shelled CA gave results comparable to SonoVue. Thus, no significant difference in the overall segment score distribution (2-47-95 vs. 1-39-104), time for clinically sufficient contrast enhancement (20-40 s for both) and left ventricular overall opacification was found. In contrast, when comparing the endocardial border delineation capacity for different regions SonoVue showed significantly higher segment scores for base and mid, except for the mid region when injecting 1.5 ml of the polymer-shelled CA. Neither high nor low doses of the polymer-shelled CA significantly affected the investigated physiological variables.
This study demonstrated that the novel polymer-shelled CA can be used in contrast-enhanced diagnostic imaging without influence on major physiological variables.
最近研发出一种具有多模态和靶向特异性潜力的新型聚合物壳造影剂（CA）。为确定其超声诊断特征，我们评估了在猪模型中可视化的心内膜边界描绘以及对生理变量的伴随影响。
使用三种剂量的新型聚合物壳CA（1.5毫升、3毫升和5毫升[5×10⁸微泡（MBs）/毫升]）以及市售CA声诺维（1.5毫升[2 - 5×10⁸MBs/毫升]）。由三名观察者独立对左心室超声图像进行视觉评估，他们将6段模型中的每个节段评为0 = 不可见、1 = 隐约可见或2 = 可见。此外，确定了临床有用的造影增强持续时间和左心室充盈度。在麻醉期间，每分钟采集一次血氧饱和度、心率和动脉压，并评估注射CA对这些生理变量的影响。
聚合物壳CA的最高剂量产生的结果与声诺维相当。因此，在总分段评分分布（2 - 47 - 95对1 - 39 - 104）、临床充分造影增强时间（两者均为20 - 40秒）和左心室整体充盈度方面未发现显著差异。相比之下，在比较不同区域的心内膜边界描绘能力时，声诺维在基底和中间部分显示出显著更高的分段评分，但注射1.5毫升聚合物壳CA时中间区域除外。聚合物壳CA的高剂量和低剂量均未对所研究的生理变量产生显著影响。
本研究表明，新型聚合物壳CA可用于造影增强诊断成像，而不影响主要生理变量。
